Cargando…

Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention

BACKGROUND: Inhabitants of Guadeloupe are chronically exposed to low doses of chlordecone via local food due to its past use in banana plantations. The corresponding health impacts have not been quantified. We develop a quantitative method and present the results in two articles: 1. Hazard identific...

Descripción completa

Detalles Bibliográficos
Autores principales: Nedellec, Vincent, Rabl, Ari, Dab, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950608/
https://www.ncbi.nlm.nih.gov/pubmed/27430869
http://dx.doi.org/10.1186/s12940-016-0159-3
_version_ 1782443582299308032
author Nedellec, Vincent
Rabl, Ari
Dab, William
author_facet Nedellec, Vincent
Rabl, Ari
Dab, William
author_sort Nedellec, Vincent
collection PubMed
description BACKGROUND: Inhabitants of Guadeloupe are chronically exposed to low doses of chlordecone via local food due to its past use in banana plantations. The corresponding health impacts have not been quantified. We develop a quantitative method and present the results in two articles: 1. Hazard identification, exposure-response functions, and exposure, 2. Health impacts, and benefits of a program to reduce the exposure of the population. Here is the second article. METHODS: The exposure-response functions derived in Part 1 (for liver and prostate cancer, renal dysfunction and cognitive development) are combined with the exposure data to calculate the impacts. The corresponding costs are calculated via DALY’s and VOLY. A no-effect threshold is included via the marginal fraction of the collective exposure above the reference dose. The health benefits are the impacts in 2002 (before the exposure reduction program) minus the impacts in 2006 (since the program). They are compared to the costs, namely the public annual expenditures for reducing the population exposure. RESULTS: Without threshold, estimated annual cases of liver cancer, prostate cancer and renal dysfunction are respectively 5.4, 2.8, 0.10 in 2002; and 2.0, 1.0, 0.04 in 2006. Annual IQ points lost (cognitive development) are respectively: 1 173 and 1 003. The annual cost of total impacts is 38.3 Million Euros (M€) in 2002 and 23.7 M€ in 2006. Comparing the benefit of 14.6 M€ with the 3.25 M€ spent for prevention, the program appears well justified. With threshold, the costs of the impacts are lower, respectively: 26.5 M€ in 2002 and 12.8 M€ in 2006, but the benefit is not very different: 13.7 M€. CONCLUSION: This is the first study that quantified chronic non genotoxic effects of chlordecone exposures in Guadeloupe. According to our results, preventive actions should be focused on pregnant women because of the high social cost of development impairment and also because their exposures decreased less rapidly than others. Prevention effort should be sustained as long as chlordecone remains in soils. Additional toxicological and epidemiological research would also be required for health endpoints that could not be taken into account (neurotoxicity of adults, autoimmune diseases and other developmental effects). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12940-016-0159-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4950608
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49506082016-07-20 Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention Nedellec, Vincent Rabl, Ari Dab, William Environ Health Research BACKGROUND: Inhabitants of Guadeloupe are chronically exposed to low doses of chlordecone via local food due to its past use in banana plantations. The corresponding health impacts have not been quantified. We develop a quantitative method and present the results in two articles: 1. Hazard identification, exposure-response functions, and exposure, 2. Health impacts, and benefits of a program to reduce the exposure of the population. Here is the second article. METHODS: The exposure-response functions derived in Part 1 (for liver and prostate cancer, renal dysfunction and cognitive development) are combined with the exposure data to calculate the impacts. The corresponding costs are calculated via DALY’s and VOLY. A no-effect threshold is included via the marginal fraction of the collective exposure above the reference dose. The health benefits are the impacts in 2002 (before the exposure reduction program) minus the impacts in 2006 (since the program). They are compared to the costs, namely the public annual expenditures for reducing the population exposure. RESULTS: Without threshold, estimated annual cases of liver cancer, prostate cancer and renal dysfunction are respectively 5.4, 2.8, 0.10 in 2002; and 2.0, 1.0, 0.04 in 2006. Annual IQ points lost (cognitive development) are respectively: 1 173 and 1 003. The annual cost of total impacts is 38.3 Million Euros (M€) in 2002 and 23.7 M€ in 2006. Comparing the benefit of 14.6 M€ with the 3.25 M€ spent for prevention, the program appears well justified. With threshold, the costs of the impacts are lower, respectively: 26.5 M€ in 2002 and 12.8 M€ in 2006, but the benefit is not very different: 13.7 M€. CONCLUSION: This is the first study that quantified chronic non genotoxic effects of chlordecone exposures in Guadeloupe. According to our results, preventive actions should be focused on pregnant women because of the high social cost of development impairment and also because their exposures decreased less rapidly than others. Prevention effort should be sustained as long as chlordecone remains in soils. Additional toxicological and epidemiological research would also be required for health endpoints that could not be taken into account (neurotoxicity of adults, autoimmune diseases and other developmental effects). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12940-016-0159-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-19 /pmc/articles/PMC4950608/ /pubmed/27430869 http://dx.doi.org/10.1186/s12940-016-0159-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Nedellec, Vincent
Rabl, Ari
Dab, William
Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention
title Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention
title_full Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention
title_fullStr Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention
title_full_unstemmed Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention
title_short Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention
title_sort public health and chronic low chlordecone exposures in guadeloupe; part 2: health impacts, and benefits of prevention
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950608/
https://www.ncbi.nlm.nih.gov/pubmed/27430869
http://dx.doi.org/10.1186/s12940-016-0159-3
work_keys_str_mv AT nedellecvincent publichealthandchroniclowchlordeconeexposuresinguadeloupepart2healthimpactsandbenefitsofprevention
AT rablari publichealthandchroniclowchlordeconeexposuresinguadeloupepart2healthimpactsandbenefitsofprevention
AT dabwilliam publichealthandchroniclowchlordeconeexposuresinguadeloupepart2healthimpactsandbenefitsofprevention